Allergan PLC (AGN)

223.92
0.85 0.38
NYSE : Health Care
Prev Close 224.77
Open 224.56
Day Low/High 223.08 / 225.65
52 Wk Low/High 184.50 / 256.80
Volume 2.00M
Avg Volume 2.01M
Exchange NYSE
Shares Outstanding 334.31M
Market Cap 76.22B
EPS 38.20
P/E Ratio N/A
Div & Yield 2.80 (1.20%)

Latest News

PayPal, Marriott International, Randgold Resources: 'Mad Money' Lightning Round

PayPal, Marriott International, Randgold Resources: 'Mad Money' Lightning Round

Jim Cramer is bullish on PayPal, Marriott International, Randgold Resources, and Kirkland Lake.

The Market Is Not About Washington: Cramer's 'Mad Money' Recap (Wed 8/16/17)

The Market Is Not About Washington: Cramer's 'Mad Money' Recap (Wed 8/16/17)

Jim Cramer says despite chaos in Washington, the market's not falling. Why? Because stocks aren't a referendum on the presidency.

Valeant Pharmaceuticals: Cramer's Top Takeaways

Valeant Pharmaceuticals: Cramer's Top Takeaways

Joe Papa, chairman and CEO of Valeant Pharmaceuticals International, talks to Jim Cramer about his company's turnaround.

Black, Jewish Goldman Executive Sues Firm Over Discriminatory Practices

Black, Jewish Goldman Executive Sues Firm Over Discriminatory Practices

A Goldman spokesman said that the firm believes the case is 'without merit' and that they will 'vigorously contest it.'

News Doesn't Alter Our Positions

Trump deflates rally a bit, but we'd buy if we could.

Teva Is Cheap, Not Dead

Teva Is Cheap, Not Dead

The drug stock deserved to go down, but the resulting selloff is an overreaction.

Why Jim Cramer Likes Allergan

Why Jim Cramer Likes Allergan

He says the stock is 'just too cheap' to pass up.

Weekly Roundup

Markets see volatility as geopolitical tensions rise. We closed out one tech position and initiated another.

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

The companies are subject to either state, federal or congressional inquiries into their marketing practices for prescription opioids, which are blamed for helping to fuel rising numbers or addicted individuals.

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Jim Cramer says we must watch the 'selfie generation' because it's changing the ways companies do business.

Valeant and Teva Share Similar Ambitions With Similar Pitfalls

Valeant and Teva Share Similar Ambitions With Similar Pitfalls

Here's what you need to know now for Wed., Aug. 9.

Cramer: Follow the Millennials

Cramer: Follow the Millennials

This generation is making its presence felt all over.

It's Time to Talk About the Russell 2000

There are 2 ways for small-caps to go, and neither one is up.

Allergan: Cramer's Top Takeaways

Allergan: Cramer's Top Takeaways

Brent Saunders, chairman and CEO of Allergan, tells Jim Cramer he's bullish on new treatments for depression.

Aegon To Sell Unirobe Meeus Groep

Aegon To Sell Unirobe Meeus Groep

This Bull Market Will Gore You, Jim Cramer Explains

This Bull Market Will Gore You, Jim Cramer Explains

Be careful.

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Jim Cramer says history doesn't have to repeat itself. You don't want to miss another opportunity in the highly visible FANG-style stocks.

Small-Cap Turnaround Stories

Small-Cap Turnaround Stories

When one of these pays off, it can make up for a number of errant wagers.

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire

All eyes are on Pfizer in the months ahead.

FDA Approves Medicines360's SNDA For LILETTA® (levonorgestrel-releasing Intrauterine System) 52 Mg To Prevent Pregnancy For Up To Four Years

FDA Approves Medicines360's SNDA For LILETTA® (levonorgestrel-releasing Intrauterine System) 52 Mg To Prevent Pregnancy For Up To Four Years

- Approval Offers Women Additional Flexibility for Pregnancy Prevention -

Are You Brave Enough to Buy Low?

Are You Brave Enough to Buy Low?

'Buy low and sell high' is easier said than done, but you can fight your fear with TEVA.

Action Alerts PLUS: There's Strength in (Earnings) Numbers

Action Alerts PLUS: There's Strength in (Earnings) Numbers

Callout: Results and guidance lift markets, dodging D.C. drama.

Teva, Mylan Seen to Stay on M&A Sidelines

Teva, Mylan Seen to Stay on M&A Sidelines

Teva is 'in no shape' to be making acquisitions while Mylan is 'still pretty leveraged,' says Oppenheimer analyst Derek Archila.